MMP2 and cancer: Treatment of cancer cells, including MDA231 and MCF7 cells, with a cellular component of DBMSCs in an IC setting, demonstrated downregulation of various effector molecules, including AKT1, CALD1, FN1, FZD7, SNA1, MMP2 and 7, STAT3, TGFB1, and vimentin, that play crucial roles in the initiation of EMT phenotypes in various cancers [59,60,61,64,69,70,73,74,75,76].